Washington state does not universally drug test every newborn. Instead, hospitals use a targeted screening approach: newborns are tested only when specific risk indicators are present in the baby or the mother. Testing is not routine, but it is common in situations where clinical signs suggest prenatal substance exposure.
When Hospitals Test a Newborn
Washington’s Department of Health guidelines are clear that newborn drug testing should be performed only when there is evidence of risk, not as a blanket policy applied to all births. Hospitals look at two categories of warning signs: those in the baby and those in the mother.
Signs in the newborn that can trigger a test include tremors or jitteriness with a normal blood sugar level, unusual irritability, unexplained seizures, a high-pitched cry, feeding problems, excessive sucking, vomiting, diarrhea, or unexplained growth restriction. These overlap heavily with symptoms of withdrawal, sometimes called neonatal abstinence syndrome.
Maternal indicators include no prenatal care, a history of drug use, precipitous (very fast) labor, placental abruption, severe mood swings, repeated miscarriages, and significant weight loss or malnutrition. Physical signs that suggest methamphetamine use, such as severe dental decay, skin abscesses, or psychiatric symptoms like hallucinations, are also listed as risk factors. A positive drug screen on the mother during pregnancy is itself an indicator for testing the baby.
The stated purpose of testing is medical treatment for the infant, not law enforcement. However, a positive result does set a reporting process in motion.
How the Testing Works
Hospitals typically test using one of two specimen types: meconium (the baby’s first stool) or umbilical cord tissue. Both detect substance exposure over a window of roughly the last several months of pregnancy, not just what was in the mother’s system at delivery.
A study at one academic medical center found that umbilical cord tissue testing flagged at least one substance in about 29% of tested specimens, compared to 21% for meconium. Non-medical drug use specifically was identified in about 10% of cord tissue samples and 8% of meconium samples. The most commonly detected substances were THC (marijuana) and amphetamines.
Cord tissue has a practical advantage: it can be collected immediately at birth, while meconium may take hours or days to pass. Meconium can also pick up medications given to the baby after birth, which can muddy results. For these reasons, many hospitals have shifted toward cord tissue testing.
Consent and Legal Authority
Washington law (RCW 70.83E) establishes a state policy of early detection of disorders caused by parental drug and alcohol use. The Department of Health is tasked with developing screening criteria and investigating testing protocols. However, the law frames this as a public health measure rather than a criminal one.
Standard newborn screening for genetic and metabolic conditions (the heel-prick blood test) is mandatory in Washington, and parents can refuse it only on religious grounds. Drug-specific toxicology screening is a separate process. It is driven by clinical judgment and risk indicators rather than a universal mandate. A provider who identifies risk factors can order a toxicology screen as part of medically necessary care for the infant.
What Happens After a Positive Test
Healthcare providers in Washington are mandated reporters. When a newborn tests positive for illicit substances, non-prescribed medications, or misused prescribed medications, clinicians are required to report to the Department of Children, Youth, and Families (DCYF). This is not optional for the provider.
A positive test does not automatically mean a child will be removed from the home. DCYF’s response depends on the circumstances. The agency is required to develop what’s called a Plan of Safe Care (POSC) for any screened-in intake involving a substance-affected newborn. This plan is meant to connect the family with services and support, not solely to investigate for removal.
If DCYF screens the report in for investigation, a caseworker will assess the situation and work with the family on a safety plan. If the report is screened out (meaning it doesn’t meet the threshold for a full investigation), the case may be referred to a program called Help Me Grow, which contacts the family and connects them to community resources like substance use treatment, parenting support, or home visiting programs.
A baby diagnosed with neonatal abstinence syndrome or showing withdrawal symptoms will receive a POSC regardless of the investigation outcome. The same applies to infants identified with fetal alcohol spectrum disorder.
How Common Substance-Exposed Births Are in Washington
Washington state has a higher rate of neonatal abstinence syndrome than the national average. In 2022, the rate was 11.2 per 1,000 live births in Washington, meaning roughly 1 in 89 babies born in the state was affected. The national rate was 6.2 per 1,000 in the most recent year with available data (2021), putting Washington’s rate at nearly double.
The state’s rate has also been climbing year over year since 2019, even as the national rate has held relatively steady. Spokane County has been flagged as a particular area of concern with rates that track above the state average.
What This Means for Expecting Parents
If you have no risk factors, your baby will almost certainly not be drug tested. The screening system is designed to be targeted, not universal. If you are taking prescribed medications during pregnancy, including opioid-based pain management or medications for opioid use disorder, let your delivery team know. These medications can cause the baby to test positive, but a positive result for a properly prescribed medication is handled very differently than one for illicit use. Your medical team can document your prescriptions and ensure the result is interpreted in context.
If you are struggling with substance use during pregnancy, engaging with prenatal care is one of the strongest protective factors. Providers who know your history can plan appropriate monitoring for the baby and connect you with support services before delivery, which generally leads to a more cooperative relationship with DCYF if a report is made. A mother actively engaged in treatment is viewed very differently than one with no prenatal care and an unexpected positive test.